ScreenerHero

NGNENeurogene Inc. Common Stock

NAS · US · Healthcare · Biotechnology · neurogene.com
38.63USDMkt Cap: 773.04M $P/E: —

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which i…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap773.04M $
Enterprise Value572.00M $
Revenue (TTM)—
Gross Profit-88.38M $
Net Income (TTM)-90.35M $
Revenue/Share—
Last Price38.63 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees131
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.34
PEG—
EV/EBITDA-4.85
EV/Revenue—
P/S—
P/B2.49
EPS (TTM)-4.86
EPS (Forward)-5.18
52W Range
37.5357% of range39.44
52W High39.44 USD
52W Low37.53 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-34.11%
ROA-31.31%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-77.17M $
CapEx (TTM)1.18M $
FCF Margin—
FCF Yield-6.22%
Net Debt-217.05M $
Net Debt/EBITDA1.84
Balance Sheet
Debt/Equity0.04
Current Ratio10.64
Quick Ratio10.50
Book Value/Sh15.23 USD
Cash/Share11.26 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:4
Split DateDec 19, 2023
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)80.43 USD
Upside (mean)+108.2%
Target Range46.00 USD – 166.00 USD
$46.00+108.2% to mean$166.00
# Analysts7
Ownership
Shares Out.20.01M
Float11.33M
Insiders6.98%
Institutions88.87%
Short Interest
Short Ratio10.9d
Short % Float17.88%
Short % Out.15.06%
Shares Short3.01M
Short (prev mo.)3.35M
Technical
SMA 5034.44 (+12.2%)
SMA 20025.54 (+51.3%)
Beta1.95
S&P 52W Chg21.00%
Avg Vol (30d)345.48K
Avg Vol (10d)192.58K
Technical Indicators
RSI (14)59.4
MACD0.9031
MACD Signal0.6357
MACD Hist.+0.2675
BB Upper39.29 USD
BB Middle35.60 USD
BB Lower31.91 USD
BB Width20.72%
ATR (14)2.396 USD
Vol Ratio (20d)1.99x